Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

被引：0
|
作者：
Cheng Huang
Xiao-Dong Zhu
Ying-Hao Shen
Dong Wu
Yuan Ji
Ning-Ling Ge
Ling-Li Chen
Chang-Jun Tan
Jian Zhou
Jia Fan
Hui-Chuan Sun
机构：
[1] Fudan University,Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital
[2] Fudan University,Department of Radiology, Zhongshan Hospital
[3] Fudan University,Department of Pathology, Zhongshan Hospital
[4] Fudan University,Department of Hepatic Oncology, Liver Cancer Institute and Zhongshan Hospital
来源：
Biomarker Research | / 9卷
关键词：
Lenvatinib; Carcinoma; Hepatocellular; Liver neoplasms; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?
    Xie, Feihu
    Feng, Shi
    Sun, Lejia
    Mao, Yilei
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (03) : 221 - 224
  • [22] An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Ndirangu, Kerigo
    Paine, Abby
    Pilkington, Hollie
    Trueman, David
    ADVANCES IN THERAPY, 2025, 42 (02) : 977 - 994
  • [23] COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Li, X.
    Wudong, G.
    Wang, Y.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [24] The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study
    Song, Danjun
    Hao, Weiyuan
    Cao, Fei
    Luo, Jun
    Guo, Liwen
    Zhang, Zhewei
    Zheng, Jiaping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
    Zhang, Wenwen
    Tong, Shuang
    Hu, Bingyang
    Wan, Tao
    Tang, Haowen
    Zhao, Feilong
    Jiao, Tianyu
    Li, Junfeng
    Zhang, Ze
    Cai, Jinping
    Ye, Huiyi
    Wang, Zhanbo
    Chen, Shiqing
    Wang, Yafei
    Li, Xuerui
    Wang, Fangzhou
    Cao, Junning
    Tian, Lantian
    Zhao, Xiaochen
    Chen, Mingyi
    Wang, Hongguang
    Cai, Shouwang
    Hu, Minggen
    Bai, Yuezong
    Lu, Shichun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [26] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Chen, Yi
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody
    Xu, Bin
    Zhu, Xiao-Dong
    Shen, Ying-Hao
    Zhu, Jin-Jin
    Liu, Jie
    Li, Mei-Ling
    Tang, Pei-Wen
    Zhou, Jian
    Fan, Jia
    Sun, Hui-Chuan
    Huang, Cheng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
    Sun, H.
    Rao, S-X.
    Xu, B.
    Zhu, X-D.
    Dong, S-Y.
    Li, X-L.
    Huang, C.
    Shen, Y-H.
    Zhu, J-J.
    Li, M-L.
    Liu, J.
    Zeng, M-S.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S825 - S826
  • [29] Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
    Qin, He-nan
    Ning, Zhen
    Sun, Rui
    Jin, Chen-xing
    Guo, Xin
    Wang, A-man
    Liu, Ji-wei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
    Li, Shuqun
    Wu, Junyi
    Wu, Jiayi
    Fu, Yangkai
    Zeng, Zhenxin
    Li, Yinan
    Li, Han
    Liao, Weijia
    Yan, Maolin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345